Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Celonic Integrates Merck’s Breez Micro-Bioreactor Platform Into Its Process Development Operations
The Breez 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture ...
According to the company, the new, 225,000-square-foot expansion is a "crucial component" of a more than $12 billion infusion ...
New facility will manufacture HPV vaccines Gardasil and Gardasil 9. Merck plans to invest $8 billion more in U.S. by 2028. A ...
Celonic Group, a Swiss-Based Quality CDMO, is integrating Merck’s Breez micro-bioreactor platform into its process ...
At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated ...
What we want to do is remove about 0.35 acres of current site wetlands, in exchange for wetlands that are already in place, ...
Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S ...
Celonic Group, a leading Swiss-based contract development and manufacturing organisation (CDMO), has integrated Merck’s Breez™ micro-bioreactor platform into its process development workflow.
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Merck & Co... We recently published a list of the 11 Best Pharma Stocks to Buy According ...
The facility integrates advanced technologies, including data analytics, generative AI, 3D printing, and a digital twin for enhanced training and process simulation. Merck's Executive Vice ...
Stocks to Consider. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other Dobermans of the Dow to buy. The Dobermans of the Dow strategy serves as an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results